IL-SILKROAD-TECHNOLOGY
28.5.2020 14:02:05 CEST | Business Wire | Press release
SilkRoad Technology, a global software and services platform that helps organisations attract, retain and align people to its business, today announced its recognition as a Core Leader in the 2020 Fosway 9-Grid™ for Talent Acquisition. This position acknowledges SilkRoad Technology for growth and innovation in its talent experience capabilities, as well as for the company's continued customer growth, success and advocacy across the European market.
SilkRoad Technology’s Talent Acquisition services and software help organisations optimise talent by attracting the right calibre of candidate to the business. HR and business decision-makers can streamline recruiting processes from requisition to job offer through SilkRoad’s scalable, personalised and on-brand solution that drives engagement and retention. Once the right talent is identified and secured, SilkRoad’s onboarding solution provides clarity, alignment and enablement to employees which helps accelerate revenue for efficient cost management in the midst of evolving workforce transformation.
“Being viewed as a Core Leader by Fosway is a great achievement for SilkRoad Technology. The Talent acquisition marketplace continues to face significant change and disruption particularly in these extremely difficult times. That’s why we continue to heavily invest finances and staff time in the development of our solution’s, so they are fit not only for today’s business challenges but also agile enough to evolve for the challenges of tomorrow as well,” said Colin Larter, Senior Director, SilkRoad EMEA.
The Fosway Group 9-Grid™ is a five-dimensional market analysis model that helps organisations understand the relative position of solutions and providers in the learning and talent systems market. It is based on Fosway Group’s independent research in the HR, talent and learning market throughout the past 20 years, and draws on insight and experience of its Corporate Research Network. The Corporate Research Network is a group of HR and learning professionals, who among them represent more than 150 of Europe’s leading companies. The 2018 Fosway 9-Grid™ for Talent Acquisition is available here .
“Silkroad is a new addition to the 2020 Fosway 9-Grid™ for Talent Acquisition. Whilst Silkroad plays in multiple parts of the talent lifecycle, its specialist focus on onboarding is central to our assessment and rating as a Core Leader,” said David Wilson, CEO of Fosway Group. “SilkRoad’s recognition reflects its proven capability to provide European companies with much needed expertise in a critical area of success.”
About Fosway
Fosway Group is Europe's #1 HR Industry Analyst. The Fosway 9-Grid provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The 9-Grids help European buyers demystify supplier decisions for next gen HR, Talent and Learning. Fosway Group have provided expert independent advice to corporate clients for over 20 years.
Visit the Fosway website at www.fosway.com for more information on Fosway Group's research and services.
About SilkRoad Technology
Since 2003, SilkRoad Technology’s software and services platform helps our clients attract, retain and align people to their business. Our solutions start with Global Client Services to provide strategic HR and business expertise. SilkRoad then designs secure solutions tailored to your business requirements at scale for global companies. We deliver personalised experiences for employees to drive engagement across the employment lifecycle to enable measurable and better business outcomes.
For more information, visit www.silkroadtechnology.com , follow on Twitter @SilkRoadTweets or call 866-329-336. (U.S. toll free) or +1-312-574-3700.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005286/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom